Effect of dopamine agonists versus levodopa as initial treatment in Parkinson’s Disease
Objective: We evaluated the efficacy of different starting drugs in the treatment of Parkinson's disease (PD), in order to further explore the initial therapy of…Pilot study of a new tool to optimize dopaminergic treatment in Parkinson’s disease: The OPTIPARK Scale Project
Objective: Our objective was to develop and pilot test a scale (OPTIPARK) for assessing a patient´s dopaminergic state, allowing the clinician to consider the adjustment…The highly selective 5-HT2A receptor antagonist EMD-281,014 alleviates L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson’s disease
Objective: To investigate the effect of the highly-selective serotonin 2A (5-HT2A ) receptor antagonist EMD-281,014 at alleviating L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesia in the 6-hydroxydopamine (6-OHDA)-lesioned rat.…Quantifying the Reproducibility of an In Vivo Assay: Examination of Historical Amantadine Effects in the macaque Model of L-DOPA-Induced Dyskinesia
Objective: This study was designed to assess the reproducibility of the amantadine anti-dyskinetic effect in the MPTP L-DOPA-Induced Dyskinesia (LID) macaque model for soundly defining…Impact of Age on Levodopa dosage regimes in Idiopathic Parkinson’s Disease
Objective: To assess the influence of patient age on prescribed dosage and subsequent dose escalation regimes of levodopa therapy in a cohort of people with…A first-in-human clinical study to test the safety and preliminary efficacy of CDNF in Parkinson’s disease
Objective: To develop a novel disease-modifying therapy in Parkinson's disease (PD) that affects both motor and non-motor symptoms, based on a novel stress-protective protein CDNF.…Bdnf rs6265 and Other Variants Predict the Efficacy of Levodopa Monotherapy in Early-Stage Parkinson’s Disease
Objective: To determine whether relatively prevalent variants in the gene for brain-derived neurotrophic factor (Bdnf) are associated with differential efficacy of levodopa or other dopaminergic…A novel non-nitrocatechol COMT inhibitor ODM-104 shows superior pharmacodynamic effects to entacapone
Objective: ODM-104 is a novel non-nitrocatechol catechol-O-methyltransferase (COMT) inhibitor that is undergoing clinical evaluation for Parkinson’s disease (PD). This study investigated the pharmacodynamic effects of…A single center retrospective analysis of Opicapone treatment in 90 Parkinson patients
Objective: To evaluate retrospectively the treatment with the novel COMT-inhibitor opicapone (OPC) in a tertiary Parkinson Center the first year after its approval in Germany…Fasciculations from a cholinesterase inhibitor
Objective: Present and discuss fasciculations in the setting of acetylcholinesterase inhibitors. Background: Specific acetylcholinesterase (AChE) inhibitors (e.g., donepezil, rivastigmine, galantamine) are the current first-line treatment…
- « Previous Page
- 1
- …
- 23
- 24
- 25
- 26
- 27
- …
- 32
- Next Page »